Traders should watch for ESMO presentation on July 4, 2026, and any updates on NMPA approval timeline. Given priority review status, approval could come in H2 2026. The 42.5% ORR in a heavily pretreated population is clinically meaningful and supports a differentiated profile vs. existing FGFR inhibitors. Consider accumulating on any pre-ESMO pullback, with stop-loss at recent support levels.
Price Chart
Executive Summary
HUTCHMED reported pivotal Phase II data for fanregratinib in FGFR2-fusion intrahepatic cholangiocarcinoma, showing a 42.5% ORR (primary endpoint met) and a manageable safety profile. The NDA has already been accepted with priority review by China's NMPA since December 2025, de-risking the regulatory path. This is a clear positive catalyst for a mid-cap biotech with an 88% bullish analyst consensus.
Key Facts
- Phase II registration trial (NCT04353375) met primary endpoint: IRC-assessed ORR of 42.5% (95% CI: 30.0%-53.6%)
- Median progression-free survival (PFS) of 6.9 months; median overall survival (OS) of 16.6 months
- Disease control rate (DCR) of 83.9% (95% CI: 74.5%-90.9%)
- NDA for fanregratinib in advanced ICC accepted and granted priority review by China NMPA in December 2025
- Fanregratinib is wholly owned by HUTCHMED worldwide with no out-licensed ex-China rights
- Treatment discontinuation due to drug-related AEs limited to 2.2%; no treatment-related deaths
- Data presented at ESMO Gastrointestinal Cancers Congress (July 2026) in a rapid oral session
Financial Impact
Fanregratinib targets a defined biomarker (FGFR2 fusion) in ICC, where approved FGFR inhibitors (Pemigatinib, Infigatinib) have shown similar sales trajectories (~$200-400M peak for second-to-market FGFR drugs). HUTCHMED retains global rights, but near-term revenues (ex-China partnership potential or China launch) are not quantifiable from this filing.
Risk Factors
- Fanregratinib is not yet approved in any jurisdiction; NMPA priority review is no guarantee of approval
- Grade ≥3 AE rate of 48.3% is notable, though discontinuation rate is low (2.2%)
- Commercial success depends on pricing/reimbursement in China and potential ex-China partnership terms
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001648257-26-000041 |
| Document: hcm-20260625x6k.htm | 0001648257-26-000041 |
| Document: 0001648257-26-000041-index-headers.html | 0001648257-26-000041 |
| Document: 0001648257-26-000041-index.html | 0001648257-26-000041 |
| Document: 0001648257-26-000041.txt | 0001648257-26-000041 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 3, 2026 29d ago | 6-K | $14.11 $12.82 | ▼ −9.14% | ▼ −7.99% | $14.24 (+0.92%) |
Aug 31, 2026 4w ago | 6-K | $12.12 $13.88 | ▲ +14.52% | ▲ +14.66% | $14.24 (+17.49%) |
Aug 18, 2026 6w ago | 6-K | $12.64 $12.26 | ▼ −3.01% | ▼ −2.81% | $14.24 (+12.66%) |
Aug 17, 2026 6w ago | 6-K | $12.56 $12.18 | ▼ −3.03% | ▼ −1.83% | $14.24 (+13.38%) |
Aug 17, 2026 6w ago | Press Release | $12.56 $12.18 | ▼ −3.03% | ▼ −1.83% | $14.24 (+13.38%) |
Jul 30, 2026 9w ago | 6-K | $10.77 $11.83 | ▲ +9.84% | ▲ +6.22% | $14.24 (+32.22%) |
Jul 2, 2026 13w ago | 6-K | $11.44 $10.98 | ▼ −4.02% | ▼ −4.95% | $14.24 (+24.48%) |
Jun 30, 2026 13w ago | 6-K | $10.76 $11.65 | ▲ +8.27% | ▲ +7.67% | $14.24 (+32.34%) |
Jun 30, 2026 13w ago | Press Release | $10.76 $11.65 | ▲ +8.27% | ▲ +7.67% | $14.24 (+32.34%) |
Jun 29, 2026 13w ago | 6-K | $10.71 $11.65 | ▲ +8.78% | ▲ +7.39% | $14.24 (+32.96%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access